CATALYST PHARMACEUTICALS, INC.·4

Nov 28, 5:00 PM ET

Del Carmen Jeffrey 4

4 · CATALYST PHARMACEUTICALS, INC. · Filed Nov 28, 2025

Insider Transaction Report

Form 4
Period: 2025-11-26
Del Carmen Jeffrey
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock, par value $0.001 per share

    2025-11-26$4.21/sh+10,983$46,23814,945 total
  • Sale

    Common Stock, par value $0.001 per share

    2025-11-26$23.33/sh10,983$256,2443,962 total
  • Exercise/Conversion

    Options to purchase common stock

    2025-11-26+10,9831,053,552 total
    Exercise: $4.21Exp: 2027-01-06Common Stock (10,983 underlying)
Footnotes (3)
  • [F1]Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.
  • [F2]Shares were sold in various lots from $23.331 to $23.345 per share. The price listed represents a weighted average price for the shares sold.
  • [F3]Options previously vested in three annual tranches beginning on January 6, 2021.

Documents

1 file
  • 4
    form_4.xmlPrimary

    FORM 4 FOR 11-26-2025